8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Dec 8, 2025·SEC
Cogent Biosciences, Inc.(COGT)Earnings, Financials & Key Ratios
COGT•NASDAQ
$35.85
$5.82B mkt cap·Price updated May 6, 2026
AboutCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$329M-21.0%
- Net Income-$329M-28.6%
- EPS (Diluted)-2.55-3.7%
- ROE-73.7%+26.0%
- ROIC-66.4%+36.0%
- Debt/Equity0.40+483.7%
- Interest Coverage-108.87
COGT Key Insights
Cogent Biosciences, Inc. (COGT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓Share count reduced 34.9% through buybacks
✗Weaknesses
- ✗Profits declining 34.5% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
COGT Price & Volume
Cogent Biosciences, Inc. (COGT) stock price & volume — 10-year historical chart
Loading chart...
COGT Growth Metrics
Cogent Biosciences, Inc. (COGT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-31.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-27.54%
Return on Capital
10 Years-60.23%
5 Years-65.72%
3 Years-78.26%
Last Year-58.19%
COGT Recent Earnings
Cogent Biosciences, Inc. (COGT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 5, 2026EPS
$0.53
Est $0.53
+0.0%
Revenue
—
Est $500
Q1 2026
Feb 17, 2026EPS
$0.55
Est $0.51
-7.8%
Revenue
—
Est $2M
Q4 2025
Nov 7, 2025EPS
$0.50
Est $0.54
+7.4%
Revenue
—
Q3 2025
Aug 5, 2025EPS
$0.53
Est $0.55
+3.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.53vs $0.53+0.0% | —vs $500 |
| Q1 2026 | Feb 17, 2026 | $0.55vs $0.51-7.8% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $0.50vs $0.54+7.4% | — |
| Q3 2025 | Aug 5, 2025 | $0.53vs $0.55+3.6% | — |
Based on last 12 quarters of dataView full earnings history →
COGT Peer Comparison
Cogent Biosciences, Inc. (COGT) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ALGS | 39.42M | 6.37 | -2.60 | -44.59% | -11.07% | -28.16% | 0.10 | |
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare COGT vs Peers
Cogent Biosciences, Inc. (COGT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COGT Income Statement
Cogent Biosciences, Inc. (COGT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.36M | 9.73M | 22.5M | 7.87M | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 31.55% | 16.44% | 131.14% | -65.02% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 43.71K | 25.74M | 0 | 0 | 0 | 0 | 4.62M | 2.33M |
| COGS % of Revenue | - | - | 0.19% | 327% | - | - | - | - | - | - |
| Gross Profit | 8.36M▲ 0% | 9.73M▲ 16.4% | 22.46M▲ 130.7% | -17.87M▼ 179.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -4.62M▲ 0% | -2.33M▲ 0% |
| Gross Margin % | 100% | 100% | 99.81% | -227% | - | - | - | - | - | - |
| Gross Profit Growth % | 31.55% | 16.44% | 130.69% | -179.57% | 100% | - | - | - | - | - |
| Operating Expenses | 34.51M | 45.74M | 54.68M | 64.33M | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M | 359.7M |
| OpEx % of Revenue | 412.82% | 469.89% | 243.02% | 817.33% | - | - | - | - | - | - |
| Selling, General & Admin | 4.68M | 7.45M | 10.97M | 17.42M | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M | 79.92M |
| SG&A % of Revenue | 55.98% | 76.58% | 48.75% | 221.34% | - | - | - | - | - | - |
| Research & Development | 29.83M | 38.28M | 43.71M | 72.65M | 55.91M | 121.63M | 173.75M | 232.66M | 269.78M | 279.78M |
| R&D % of Revenue | 356.84% | 393.31% | 194.27% | 922.98% | - | - | - | - | - | - |
| Other Operating Expenses | 274K | 320K | 78K | -25.74M | 0 | 0 | 0 | 0 | -4.62M | 0 |
| Operating Income | -26.15M▲ 0% | -36.01M▼ 37.7% | -32.18M▲ 10.6% | -82.2M▼ 155.5% | -75.55M▲ 8.1% | -147.84M▼ 95.7% | -208.13M▼ 40.8% | -275.94M▼ 32.6% | -333.36M▼ 20.8% | -362.04M▲ 0% |
| Operating Margin % | -312.82% | -369.89% | -143.02% | -1044.33% | - | - | - | - | - | - |
| Operating Income Growth % | -37.14% | -37.68% | 10.63% | -155.45% | 8.09% | -95.68% | -40.78% | -32.58% | -20.81% | - |
| EBITDA | -24.98M | -34.68M | -30.89M | -81.48M | -73.56M | -141.96M | -204.54M | -271.59M | -328.74M | -363.18M |
| EBITDA Margin % | -298.82% | -356.32% | -137.27% | -1035.18% | - | - | - | - | - | - |
| EBITDA Growth % | -36.96% | -38.84% | 10.95% | -163.81% | 9.72% | -92.99% | -44.08% | -32.78% | -21.05% | -27.86% |
| D&A (Non-Cash Add-back) | 1.17M | 1.32M | 1.29M | 720K | 1.99M | 5.88M | 3.59M | 4.35M | 4.62M | -1.14M |
| EBIT | -26.15M | -36.01M | -32.18M | -35.29M | -75.55M | -147.84M | -208.13M | -275.94M | -333.36M | -258.43M |
| Net Interest Income | 386K | 1.15M | 267K | 144K | 467K | 0 | 13.08M | 18.09M | 11.63M | 8.68M |
| Interest Income | 386K | 1.15M | 267K | 144K | 467K | 3.99M | 13.08M | 18.09M | 14.69M | 19.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 3.99M | 0 | 0 | 3.06M | 1.85M |
| Other Income/Expense | 660K | 1.47M | 345K | 7.39M | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M | 7.73M |
| Pretax Income | -25.49M▲ 0% | -34.53M▼ 35.5% | -31.83M▲ 7.8% | -74.81M▼ 135.0% | -72.27M▲ 3.4% | -140.24M▼ 94.0% | -192.41M▼ 37.2% | -255.86M▼ 33.0% | -328.94M▼ 28.6% | -354.3M▲ 0% |
| Pretax Margin % | -304.93% | -354.76% | -141.49% | -950.43% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -25.49M▲ 0% | -34.53M▼ 35.5% | -30.27M▲ 12.3% | -74.81M▼ 147.1% | -72.27M▲ 3.4% | -140.24M▼ 94.0% | -192.41M▼ 37.2% | -255.86M▼ 33.0% | -328.94M▼ 28.6% | -354.3M▲ 0% |
| Net Margin % | -304.93% | -354.76% | -134.55% | -950.43% | - | - | - | - | - | - |
| Net Income Growth % | -40.65% | -35.46% | 12.33% | -147.11% | 3.39% | -94.04% | -37.2% | -32.98% | -28.56% | -31.47% |
| Net Income (Continuing) | -25.49M | -34.53M | -31.83M | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M | -328.94M | -354.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.45▲ 0% | -5.55▼ 60.9% | -3.97▲ 28.5% | -6.00▼ 51.1% | -1.85▲ 69.2% | -2.26▼ 22.2% | -2.42▼ 7.1% | -2.46▼ 1.7% | -2.55▼ 3.7% | -5.26▲ 0% |
| EPS Growth % | -40.82% | -60.87% | 28.47% | -51.13% | 69.17% | -22.16% | -7.08% | -1.65% | -3.66% | -27.54% |
| EPS (Basic) | -3.45 | -5.55 | -3.97 | -6.00 | -1.85 | -2.26 | -2.42 | -2.46 | -2.55 | - |
| Diluted Shares Outstanding | 7.4M | 6.22M | 7.62M | 11.08M | 38.73M | 58.74M | 79.66M | 103.86M | 67.6M | 67.41M |
| Basic Shares Outstanding | 7.4M | 6.22M | 7.62M | 11.08M | 38.73M | 58.74M | 79.66M | 103.86M | 67.6M | 67.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
COGT Balance Sheet
Cogent Biosciences, Inc. (COGT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 42.38M | 81M | 40.59M | 244.91M | 222.63M | 264.97M | 270.77M | 296.47M | 910.36M | 877.8M |
| Cash & Short-Term Investments | 40.96M | 78.59M | 37.42M | 242.19M | 219.68M | 259.28M | 265.71M | 287.08M | 900.76M | 866.38M |
| Cash Only | 28.27M | 55.67M | 37.42M | 242.19M | 219.68M | 139.89M | 53.23M | 98.17M | 312.01M | 241.21M |
| Short-Term Investments | 12.69M | 22.92M | 0 | 0 | 0 | 119.39M | 212.48M | 188.91M | 588.75M | 625.17M |
| Accounts Receivable | 830K | 1.67M | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 36.24 | 62.55 | 32.45 | - | - | - | - | - | - | - |
| Inventory | 75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 75K | 740K | 0 | 0 | 0 | 1.25M | 5.06M | 9.39M | 9.59M | 11.43M |
| Total Non-Current Assets | 6.74M | 4.92M | 8.83M | 6M | 9.46M | 35.84M | 42.67M | 31.43M | 27.25M | 25.2M |
| Property, Plant & Equipment | 4.11M | 3.25M | 7.15M | 4.75M | 4.48M | 31.1M | 30.34M | 26.56M | 23.54M | 22.85M |
| Fixed Asset Turnover | 2.04x | 2.99x | 3.15x | 1.66x | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.25M | 1.25M | 0 | 0 | 0 | 0 | 7.46M | 0 | 0 | 0 |
| Other Non-Current Assets | 1.37M | 419K | 1.68M | 1.25M | 4.98M | 4.75M | 4.86M | 4.86M | 3.72M | 15.76M |
| Total Assets | 49.12M▲ 0% | 85.93M▲ 75.0% | 49.42M▼ 42.5% | 250.92M▲ 407.7% | 232.09M▼ 7.5% | 300.81M▲ 29.6% | 313.44M▲ 4.2% | 327.9M▲ 4.6% | 937.61M▲ 185.9% | 903.01M▲ 0% |
| Asset Turnover | 0.17x | 0.11x | 0.46x | 0.03x | - | - | - | - | - | 0.00x |
| Asset Growth % | -34.99% | 74.95% | -42.48% | 407.69% | -7.5% | 29.61% | 4.2% | 4.61% | 185.94% | 378.97% |
| Total Current Liabilities | 11.19M | 24.95M | 13.25M | 13.09M | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M | 57.98M |
| Accounts Payable | 1.35M | 1.52M | 3.18M | 732K | 3.48M | 5.84M | 10.65M | 12.01M | 9.5M | 13.74M |
| Days Payables Outstanding | - | - | 26.58K | 10.38 | - | - | - | - | 751.02 | 2.19K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.55M | 1.38M |
| Deferred Revenue (Current) | 6.89M | 17.95M | 1.31M | 0 | 3.06M | 1.7M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.64M | 3.88M | 3.39M | 7.28M | 3.62M | 6.47M | 10.31M | 12.63M | 52.9M | 42.85M |
| Current Ratio | 3.79x | 3.25x | 3.06x | 18.70x | 13.04x | 9.87x | 7.09x | 5.32x | 14.23x | 14.23x |
| Quick Ratio | 3.78x | 3.25x | 3.06x | 18.70x | 13.04x | 9.87x | 7.09x | 5.32x | 14.23x | 14.23x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 9.62M | 748K | 4.41M | 3.15M | 831K | 18.23M | 17.47M | 15.9M | 237.28M | 237.33M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 237.25M | 237.27M |
| Capital Lease Obligations | 0 | 0 | 4.41M | 3.15M | 831K | 18.23M | 17.47M | 15.9M | 14.36M | 44.01M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 906K | 748K | 0 | 0 | 0 | 0 | 0 | 0 | -14.32M | -9.53M |
| Total Liabilities | 20.81M | 25.69M | 17.66M | 16.25M | 17.91M | 45.08M | 55.63M | 71.61M | 301.24M | 295.31M |
| Total Debt | 0 | 0 | 6.03M | 5.21M | 3.15M | 19.65M | 18.85M | 17.47M | 253.15M | 238.65M |
| Net Debt | -28.27M | -55.67M | -31.39M | -236.98M | -216.53M | -120.24M | -34.38M | -80.7M | -58.86M | -2.56M |
| Debt / Equity | - | - | 0.19x | 0.02x | 0.01x | 0.08x | 0.07x | 0.07x | 0.40x | 0.40x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.66x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.01x |
| Interest Coverage | - | - | - | - | - | -37.06x | - | - | -108.87x | -139.77x |
| Total Equity | 28.3M▲ 0% | 60.23M▲ 112.8% | 31.76M▼ 47.3% | 234.67M▲ 638.8% | 214.18M▼ 8.7% | 255.74M▲ 19.4% | 257.8M▲ 0.8% | 256.29M▼ 0.6% | 636.37M▲ 148.3% | 607.69M▲ 0% |
| Equity Growth % | -45.97% | 112.8% | -47.27% | 638.83% | -8.73% | 19.4% | 0.81% | -0.59% | 148.31% | 263.46% |
| Book Value per Share | 3.83 | 9.68 | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | 2.47 | 9.41 | 9.01 |
| Total Shareholders' Equity | 28.3M | 60.23M | 31.76M | 234.67M | 214.18M | 255.74M | 257.8M | 256.29M | 636.37M | 607.69M |
| Common Stock | 10K | 30K | 8K | 32K | 44K | 70K | 86K | 110K | 161K | 171K |
| Retained Earnings | -51.34M | -92.06M | -123.89M | -198.7M | -270.97M | -411.21M | -603.62M | -859.48M | -1.19B | -1.29B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -16K | -12K | 0 | 0 | 0 | -104K | 246K | 447K | 355K | -415K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGT Cash Flow Statement
Cogent Biosciences, Inc. (COGT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -25.84M | -32.49M | -41.51M | -35.85M | -58.76M | -118.64M | -153.62M | -207.79M | -264.44M | -264.44M |
| Operating CF Margin % | -309.03% | -333.77% | -184.51% | -455.47% | - | - | - | - | - | - |
| Operating CF Growth % | -38.6% | -25.76% | -27.78% | 13.64% | -63.91% | -101.89% | -29.49% | -35.26% | -27.26% | -112.61% |
| Net Income | -25.49M | -34.53M | -31.83M | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M | -328.94M | -354.3M |
| Depreciation & Amortization | 1.17M | 1.32M | 1.29M | 720K | 147K | 5.88M | 3.59M | 4.35M | 4.58M | 4.64M |
| Stock-Based Compensation | 1.34M | 3.09M | 3.24M | 6.02M | 11.69M | 18.37M | 30.62M | 39.74M | 46.08M | 37.23M |
| Deferred Taxes | 17K | -236K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7K | 23K | -131K | 37.54M | -343K | -3.39M | -6.87M | -7.62M | 5.82M | 14.9M |
| Working Capital Changes | -2.88M | -2.15M | -14.08M | -5.32M | 2.02M | 751K | 11.44M | 11.6M | 8.01M | 12.73M |
| Change in Receivables | 98K | -838K | -332K | 2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 931K | 2.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -31K | 367K | 1.66M | -2.45M | 2.75M | 2.36M | 4.81M | 1.36M | -2.51M | -410K |
| Cash from Investing | 13.51M | -10.53M | 23.16M | 8.42M | -1.72M | -124.72M | -97.82M | 38.28M | -399.53M | -505.36M |
| Capital Expenditures | -912K | -549K | -33K | 0 | -1.72M | -6.86M | -2.8M | -573K | -1.55M | -1.46M |
| CapEx % of Revenue | 10.91% | 5.64% | 0.15% | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 204K | 0 | 0 | 117.86K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -75K | 0 | 0 | 8.42M | 0 | -117.86K | 0 | 0 | 0 | 0 |
| Cash from Financing | -729K | 70.35M | 108K | 232.2M | 37.98M | 163.56M | 163.54M | 214.45M | 878.23M | 905.8M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 215.13M | 215.13M |
| Equity Issued (Net) | 60K | 71.79M | 108K | 231.64M | 38.01M | 161.94M | 163.54M | 213.34M | 712M | 687.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M |
| Other Financing | -789K | -1.45M | 0 | 560K | -30K | 1.61M | 0 | 1.11M | -48.9M | 3.64M |
| Net Change in Cash | -13.05M▲ 0% | 27.33M▲ 309.4% | -18.25M▼ 166.8% | 204.77M▲ 1222.2% | -22.51M▼ 111.0% | -79.8M▼ 254.6% | -87.91M▼ 10.2% | 44.94M▲ 151.1% | 214.26M▲ 376.8% | 115.2M▲ 0% |
| Free Cash Flow | -26.75M▲ 0% | -33.04M▼ 23.5% | -41.55M▼ 25.8% | -35.85M▲ 13.7% | -60.48M▼ 68.7% | -125.5M▼ 107.5% | -156.42M▼ 24.6% | -208.36M▼ 33.2% | -266M▼ 27.7% | -286.27M▲ 0% |
| FCF Margin % | -319.94% | -339.41% | -184.66% | -455.47% | - | - | - | - | - | - |
| FCF Growth % | -21.87% | -23.52% | -25.76% | 13.71% | -68.71% | -107.5% | -24.64% | -33.21% | -27.66% | -28.48% |
| FCF per Share | -3.62 | -5.31 | -5.45 | -3.24 | -1.56 | -2.14 | -1.96 | -2.01 | -3.93 | -3.93 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.94x | 1.37x | 0.48x | 0.81x | 0.85x | 0.80x | 0.81x | 0.80x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGT Key Ratios
Cogent Biosciences, Inc. (COGT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -63.18% | -78% | -65.81% | -56.16% | -32.2% | -59.69% | -74.94% | -99.54% | -73.7% | -83.29% |
| Return on Invested Capital (ROIC) | -353.34% | -1174.59% | -978.45% | - | - | -166.54% | -86.98% | -103.73% | -66.4% | -66.4% |
| Gross Margin | 100% | 100% | 99.81% | -227% | - | - | - | - | - | - |
| Net Margin | -304.93% | -354.76% | -134.55% | -950.43% | - | - | - | - | - | - |
| Debt / Equity | - | - | 0.19x | 0.02x | 0.01x | 0.08x | 0.07x | 0.07x | 0.40x | 0.40x |
| Interest Coverage | - | - | - | - | - | -37.06x | - | - | -108.87x | -139.77x |
| FCF Conversion | 1.01x | 0.94x | 1.37x | 0.48x | 0.81x | 0.85x | 0.80x | 0.81x | 0.80x | 0.81x |
| Revenue Growth | 31.55% | 16.44% | 131.14% | -65.02% | -100% | - | - | - | - | - |
COGT SEC Filings & Documents
Cogent Biosciences, Inc. (COGT) SEC filings — annual & quarterly reports (10-K, 10-Q)
COGT Frequently Asked Questions
Cogent Biosciences, Inc. (COGT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cogent Biosciences, Inc. (COGT) grew revenue by 0.0% over the past year. Growth has been modest.
Cogent Biosciences, Inc. (COGT) reported a net loss of $354.3M for fiscal year 2025.
Dividend & Returns
Cogent Biosciences, Inc. (COGT) has a return on equity (ROE) of -73.7%. Negative ROE indicates the company is unprofitable.
Cogent Biosciences, Inc. (COGT) had negative free cash flow of $286.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More COGT
Cogent Biosciences, Inc. (COGT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates